Lee SH, et al. - The researchers evaluated the efficacy and safety of adding omarigliptin to the treatment regimen of patients with type 2 diabetes (T2D) inadequately controlled by dual therapy with metformin and glimepiride. Once-weekly omarigliptin provided greater improvement in glycemic control and was generally well tolerated in patients with T2D and inadequate glycemic control on dual therapy with metformin and glimepiride, compared with placebo.